吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
对124名法国患者的进一步研究提示，运用该模型，认为无风险的患者中位生存期为378天，有风险的只有90天。
Study of a further 124 French patients showed that those deemed at good risk using the model, had a median survival of 378 days, compared to 90 days in the poor risk group.
在治疗结束时，蛋白酶体水平升高患者的中位生存期是30.2个月。蛋白酶体水平恢复正常的患者没有观察到终点事件。
Median survival at the end of treatment was 30.2 months in patients with elevated levels. This point was not reached in patients with normalized levels.
接受氟尿嘧啶联合亚叶酸方案治疗或是吉西他滨方案治疗患者的中位生存期分别为23.0个月及23.6个月。
Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.
血浆中egfr外显子19删除患者的中位生存期要明显好于那些存在L 858r变异患者(32个月相对14个月)。
Median survival time for patients with an EGFR exon 19 deletion in serum was also substantially higher than in those with L858R mutations (32 months vs 14 months).
这项试验中，31名患者被纳入研究，5名患者反应良好，疾病稳定，中位生存期为4.4个月。
In this study with 31 patients enrolled thus far, the best response was stable disease in 5 patients with a median OS of 4.4 months.
另外，对5例化疗患者和10例非化疗患者(均为高危组MDS患者)进行中位生存期和生存率比较。
Besides, compare median survival time with survival rate for 5 cases of chemotherapy group and 10 cases of non-chemotherapy group (the high-risk group of MDS patients). Results: 1.
可以确切延长中位生存期，提高患者生存质量。
It can prolong the patients' life and improve their quality of life.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
所有患者中位随访时间35.8个月，80例出现复发或转移，40例死亡，中位生存期未达到，中位无疾病生存期（DFS）为24.1个月。
After a median follow-up of 35.8 months, 80 patients experienced metastatic or recurrent tumors and 40 patients died. The median overall survival was not reached and the median DFS was 24.1 months.
应用推荐